Can Studying Genetically Predisposed Individuals Inform Prevention Strategies for RA?

• Published in: Healthcare
• Main Authors: Amanda Fowler-Woods, Irene Smolik, Vidyanand Anaparti, Liam O’Neil, Hani El-Gabalawy
• Format: Article in Journal/Newspaper
• Language: English
• Published: MDPI AG 2021
• Subjects: rheumatoid arthritis; autoimmune disorder; prevention; risk; Indigenous population; First Nations; Medicine; R
• Online Access: https://doi.org/10.3390/healthcare9101301; https://doaj.org/article/3f0dff16d3c8491894a7d1f89c7ec0a2

Rheumatoid arthritis (RA) is a prevalent autoimmune disorder in which complex genetic predisposition interacts with multiple environmental factors to precipitate chronic and progressive immune-mediated joint inflammation. Currently, in most affected individuals, ongoing suppression of the inflammation is required to prevent irreversible damage and functional loss. The delineation of a protracted preclinical period in which autoimmunity is initially established and then evolves to become pathogenic provides unprecedented opportunities for interventions that have the potential to prevent the onset of this lifelong disease. Clinical trials aimed at assessing the impact of specific prevention strategies require the identification of individuals who are at high risk of future RA development. Currently, these risk factors include a strong family history of RA, and the detection of circulating RA-associated autoantibodies, particularly anti-citrullinated protein antibodies (ACPA). Yet, even in such individuals, there remains considerable uncertainty about the likelihood and the timeframe for future disease development. Thus, individuals who are approached to participate in such clinical trials are left weighing the risks and benefits of the prevention measures, while having large gaps in our current understanding. To address this challenge, we have undertaken longitudinal studies of the family members of Indigenous North American RA patients, this population being known to have a high prevalence of RA, early age of onset, and familial clustering of cases. Our studies have indicated that the concepts of “risk” and “prevention” need to be communicated in a culturally relevant manner, and proposed prevention interventions need to have an appropriate balance of effectiveness, safety, convenience, and cultural acceptability. We have focused our proposed prevention studies on immunomodulatory/anti-inflammatory nutritional supplements that appear to strike such a complex balance.